teleo-codex/inbox/queue/2026-03-lancetpsychiatry-glp1-mental-illness-swedish-cohort.md

type	title	author	url	date	domain	secondary_domains	format	status	priority	tags	intake_tier
source	GLP-1 receptor agonists associated with 42% lower risk of worsening mental illness in Swedish national cohort (within-individual design)	Lancet Psychiatry / Karolinska Institutet	https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00014-3/fulltext	2026-03-22	health		research-article	unprocessed	high	GLP-1 semaglutide mental-health depression anxiety substance-use-disorder within-individual-design Swedish-cohort psychiatric-safety divergence	research-task

Content

Lancet Psychiatry, March 2026. Karolinska Institutet (Swedish national registry study). Study: "Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden."

Study design:

• n = 95,490 people with pre-existing depression and/or anxiety
• 22,480 used GLP-1 receptor agonists during follow-up
• WITHIN-INDIVIDUAL stratified Cox models — compares same person's periods ON vs. OFF GLP-1
• This design eliminates ALL time-invariant confounding (baseline psychiatric severity, comorbidities, social circumstances)
• Primary outcome: composite of psychiatric hospitalization, sick leave >14 days for psychiatric reasons, hospitalization for self-harm, death by suicide

Key findings (semaglutide):

• 42% lower risk of worsening mental illness during semaglutide use vs. non-use periods (same individuals)
• Depression worsening: HR 0.56, 95% CI [0.44-0.71] → 44% reduction
• Anxiety worsening: HR 0.62, 95% CI [0.52-0.73] → 38% reduction
• Substance use disorder worsening: HR 0.53, 95% CI [0.35-0.80] → 47% reduction
• Self-harm: 47% reduction

Liraglutide: HR 0.82 for overall mental illness worsening → 18% reduction (weaker effect)

Why this resolves the divergence:

• The matched cohort study (Nature Scientific Reports, 162,253 patients) showed 195% INCREASED MDD risk in GLP-1 users
• The within-individual design demonstrates that the matched cohort finding is likely a SELECTION ARTIFACT: people prescribed GLP-1s have more baseline psychiatric comorbidity; propensity score matching cannot fully eliminate this (confounding by unobserved variables)
• Within-individual comparison strips away time-invariant confounders, showing the drug itself is associated with BETTER mental health outcomes when prescribed to people with pre-existing illness
• The FDA meta-analysis of 91 placebo-controlled RCTs (107,910 patients) also found NO increased psychiatric risk → converges with the Swedish study

Study limitation: Population is people with pre-existing depression/anxiety — may not generalize to patients without mental health history.

Karolinska Institutet press coverage: "Diabetes drug Ozempic linked to better mental health" — published same day.

Agent Notes

Why this matters: This is the methodologically dominant evidence in the GLP-1 psychiatric safety debate. The within-individual design is the strongest quasi-experimental design available in observational epidemiology for this question — it eliminates the confounding by indication that plagues all matched cohort studies of GLP-1s. The 42-47% reductions in depression, anxiety, and SUD worsening are large effects. This should trigger a significant confidence update on GLP-1 psychiatric safety and should be documented as the study that resolves the apparent divergence.

What surprised me: The magnitude. A 44% reduction in depression worsening and 47% reduction in SUD worsening during semaglutide use periods — in people with pre-existing mental illness — is larger than any approved psychiatric medication for these conditions. If this effect size replicates in RCTs, GLP-1s would become first-line adjunct psychiatric medications.

What I expected but didn't find: Formal acknowledgment in existing KB claims that the Swedish study resolves the 195% MDD risk signal. The prior session archive (2026-05-02) documented both findings as in tension — this session clarifies that the within-individual design should dominate.

KB connections:

• GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035 — safety profile is better than prior signals suggested
• the mental health supply gap is widening not closing — GLP-1s addressing depression/anxiety/SUD could partially offset the supply gap through pharmacological means
• medical care explains only 10-20 percent of health outcomes — GLP-1s challenge the clean clinical/non-clinical boundary by addressing non-clinical pathways through clinical drugs
• Divergence candidate: GLP-1 psychiatric safety — matched cohort (195% MDD risk) vs. within-individual (42% reduction in worsening)

Extraction hints:

• Primary claim: "Semaglutide reduces worsening of depression, anxiety, and substance use disorder by 40-50% in people with pre-existing mental illness (Lancet Psychiatry, within-individual design, n=95,490)"
• Divergence document: GLP-1 psychiatric safety — within-individual vs. matched cohort design conflict
• Belief 2 complication: clinical drug achieving large effects on behavioral/non-clinical health pathways

Context: Published alongside Science Media Centre expert reactions. Medscape covered as "GLP-1s Tied to Lower Risk of Psychiatric Decline in Pre-existing Mental Illness." ScienceDaily: "Weight loss drug Ozempic cuts depression, anxiety, and addiction risk."

Curator Notes (structured handoff for extractor)

PRIMARY CONNECTION: GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035 WHY ARCHIVED: This is the methodologically strongest study on GLP-1 psychiatric safety — resolves the 195% MDD risk divergence by demonstrating confounding by indication; the within-individual finding has no precedent in the KB EXTRACTION HINT: Write two outputs: (1) new claim on semaglutide's psychiatric protective effects (HR 0.56 for depression), (2) divergence document explaining why the matched cohort and within-individual results both exist and which to weight more heavily